According to a major international study, Switzerland has once again fallen behind other European countries in terms of access to new innovative medicines – from sixth to seventh place. Particularly worrying is the fact that, compared to Germany, only around half as many new innovative medicines are reimbursed as standard via the specialty list.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Autoimmune Liver Diseases
Innovative Treatment Approaches for PBC, PSC, and AIH: What’s New?
- Myelofibrosis
Mutations and Molecular Diagnostics in Treatment Decisions
- Psoriasis in the Age of Precision Medicine
Systemic Therapy for Patients with Comorbidities: What Is the Best Choice?
- The AMALFI study and the limits of digital screening for atrial fibrillation
Remote monitoring for atrial fibrillation: lots of detection, little stroke prevention?
- MASH
Pharmacotherapies as “Game Changers”—What Are the Upcoming Challenges?
- Obesity Treatment
Oral GLP-1 Therapies: ATTAIN-1 and OASIS-4—The Next Leap Forward
- Older patients with atopic dermatitis
Why the Use of Biologics Is Recommended
- Disorders of the Gut-Brain Interaction